<DOC>
	<DOCNO>NCT01695434</DOCNO>
	<brief_summary>To explore whether treatment glatiramer acetate ( GA ) may decrease iron deposition subcortical deep GM , detect SWI-filtered phase imaging , patient RRMS 24 month compare reference population healthy control .</brief_summary>
	<brief_title>A Longitudinal Study Effect Copaxone RRMS Over 24 Months</brief_title>
	<detailed_description>This prospective , observational , single-blinded , longitudinal , 24-month MRI study evolution iron deposit , evidence SWI-filtered phase imaging , RRMS patient treat GA healthy control .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>MS patient diagnose clinically definite MS accord McDonald criterion ( Polman et al. , 2005 ) Being GA monotherapy ( 20mg/day sc ) least 24 month prior 24month MRI scan Having baseline clinical MRI scan include SWIfiltered phase image 12month window start day GA ( MS patient ) Having baseline clinical MRI scan include SWIfiltered phase imaging ( healthy control ) MS patient RR disease course ( Lublin Reingold , 1996 ) Age 1865 ( healthy control match MS patient age sex ) Signed informed consent 24month followup Pass MRI health screen MS patient pass contrast screen MS patient normal kidney function ( creatinine clearance &gt; 59 ) None exclusion criterion Patients relapse within 30 day prior MRI baseline scan date Patients receive steroid treatment within 30 day prior MRI baseline scan date Women pregnant , lactate childbearing age consent approve contraceptive use study MS patient use imunomodulatory immunosuppressant treatment GA followup ( e.g. , IFNÎ² , mitoxantrone , cyclophosphamide , cladribine , fludarabine , cyclosporine , total body , azathioprine , methotrexate , IVIG , cellcept , natalizumab , etc . ) MS patient abnormal kidney function ( creatinine clearance &lt; 59 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MRI</keyword>
	<keyword>Copaxone</keyword>
	<keyword>healthy control</keyword>
	<keyword>glatiramer acetate</keyword>
</DOC>